RepliCel Life Science Inc. (TSXV:RP) is a regenerative medicine company focused on developing autologous cell therapies that address conditions linked to a deficit of healthy cells required for normal healing and function. Speaking from the 2015 CIX Public Investors Top 20 day, CEO and President Lee Buckler said, “We are changing the paradigm of the way we treat people to really be curative instead of attacking symptoms.” The company is expected to see 36 months of work be culminated into one big milestone in 2016.
CIX 2015 Companies To Watch: Replicel Life Sciences Inc. (TSXV:RP)
Published: